Viking Therapeutics VKTX Cash Flow Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| -$359.64M-227% | -$109.96M-28.0% | -$85.9M-24.7% | -$68.87M-25.2% | ||
| $40.82M+37.4% | $29.71M+77.4% | $16.75M+93.1% | $8.67M+42.2% | ||
| $43.44M+1,786% | $2.3M— | —— | —— | ||
| —— | —— | —— | $5.81M+1,248% | ||
| —— | —— | -$6.47M— | —— | ||
| $431K+24.6% | $346K+18.5% | $292K+0.3% | $291K— | ||
| -$505K-25.6% | -$402K-15.9% | -$347K-83.6% | -$189K+44.7% | ||
| -$278.69M-217% | -$87.79M-19.6% | -$73.38M-51.6% | -$48.4M-1.7% | ||
| $418.04M-62.5% | $1.11B+133% | $478.3M+294% | $121.43M-27.7% | ||
| $759.43M+35.6% | $560M+87.2% | $299.22M+69.8% | $176.18M-14.5% | ||
| $341.39M— | —— | —— | $54.75M+44.2% | ||
| —— | —— | —— | —— | ||
| —— | —— | —— | —— | ||
| $76.44M-87.5% | $612.46M+126% | $271.45M+6,421% | $4.16M-41.7% | ||
| —— | -$151K— | —— | —— | ||
| $143.19M— | —— | —— | $10.52M— | ||
| $9.28M-46.2% | $17.27M+111% | $8.2M+774% | -$1.22M+68.8% | ||
| $56K-40.4% | $94K+6.8% | $88K+49.2% | $59K+211% | ||
| -$505K-25.6% | -$402K-15.9% | -$347K-83.6% | -$189K+44.7% | ||
| —— | —— | -$6.47M— | —— | ||
| $431K+24.6% | $346K+18.5% | $292K+0.3% | $291K— | ||
| —— | $38K-11.6% | $43K+4.9% | $41K+273% | ||
| $759.43M+35.6% | $560M+87.2% | $299.22M+69.8% | $176.18M-14.5% | ||
| $73.95M— | —— | —— | $11.67M— | ||
| —— | —— | —— | —— | ||
| —— | -$151K— | —— | —— | ||
| -$505K-25.6% | -$402K-15.9% | -$347K-83.6% | -$189K+44.7% | ||
| $0-100% | $223K— | $0— | —— | ||
| —— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Viking Therapeutics's cash flow data come from?
- Every line is extracted from Viking Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.